Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic DystrophyBusiness Wire • 11/28/23
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare ConferenceBusiness Wire • 11/21/23
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare ConferenceBusiness Wire • 11/06/23
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023Business Wire • 11/02/23
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 ConferencesBusiness Wire • 10/03/23
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 ConferencesBusiness Wire • 09/01/23
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular DystrophyBusiness Wire • 07/17/23
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1Business Wire • 06/27/23
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver DiseaseBusiness Wire • 06/24/23
Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung DiseaseInvestors Business Daily • 06/01/23
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFHBusiness Wire • 05/23/23
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia SyndromeBusiness Wire • 05/16/23